Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.

Unseld M, Filip M, Seirl S, Gleiss A, Bianconi D, Kieler M, Demyanets S, Scheithauer W, Zielinski C, Prager G.

Neoplasma. 2018;65(4):599-603. doi: 10.4149/neo_2018_170727N506.

PMID:
29940763
2.

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe LM, Etienne PL, Mineur L, Clisant S, Phelip JM, Kramar A, Andre T.

BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9. Erratum in: BMC Cancer. 2016 Jul 25;16(1):518.

3.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
4.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.

Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL.

Cancer Treat Rev. 2018 Jan;62:61-73. doi: 10.1016/j.ctrv.2017.10.011. Epub 2017 Nov 10. Review.

PMID:
29175677
5.

Regorafenib: A Review in Metastatic Colorectal Cancer.

Dhillon S.

Drugs. 2018 Jul;78(11):1133-1144. doi: 10.1007/s40265-018-0938-y. Review.

PMID:
29943375
6.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.

Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.

PMID:
23177514
7.

Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.

Petrioli R, Chirra M, Messuti L, Fiaschi AI, Savelli V, Martellucci I, Francini E.

Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21.

PMID:
29548772
8.
9.

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J.

Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19.

10.

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.

Yoshino K, Manaka D, Kudo R, Kanai S, Mitsuoka E, Kanto S, Hamasu S, Konishi S, Nishitai R.

J Med Case Rep. 2017 Aug 18;11(1):227. doi: 10.1186/s13256-017-1366-4.

11.

Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.

Unseld M, Drimmel M, Siebenhüner A, Gleiss A, Bianconi D, Kieler M, Scheithauer W, Winder T, Prager GW.

Clin Colorectal Cancer. 2018 Dec;17(4):274-279. doi: 10.1016/j.clcc.2018.05.012. Epub 2018 Jun 8.

PMID:
30042010
12.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.

Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187.

13.

Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ, Erdoğan B.

Cancer Chemother Pharmacol. 2019 Jan;83(1):115-122. doi: 10.1007/s00280-018-3713-6. Epub 2018 Oct 29.

PMID:
30374523
14.

Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.

Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K.

Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2.

PMID:
28866662
15.

Regorafenib in the treatment of metastatic colorectal cancer.

de la Fouchardière C.

Future Oncol. 2018 Sep;14(22):2239-2246. doi: 10.2217/fon-2017-0512. Epub 2018 Mar 23. Review.

PMID:
29569472
16.

Regorafenib in the treatment of colorectal cancer.

Majithia N, Grothey A.

Expert Opin Pharmacother. 2016;17(1):137-45. doi: 10.1517/14656566.2016.1118054. Epub 2015 Dec 4. Review.

PMID:
26559195
17.

A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.

Abrahao ABK, Ko YJ, Berry S, Chan KKW.

Clin Colorectal Cancer. 2018 Jun;17(2):113-120. doi: 10.1016/j.clcc.2017.10.016. Epub 2017 Nov 22.

PMID:
29174481
18.

Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

García-Alfonso P, Feliú J, García-Carbonero R, Grávalos C, Guillén-Ponce C, Sastre J, García-Foncillas J.

Clin Transl Oncol. 2016 Nov;18(11):1072-1081. Epub 2016 Apr 1. Review.

PMID:
27037815
19.

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.

Sastre J, Argilés G, Benavides M, Feliú J, García-Alfonso P, García-Carbonero R, Grávalos C, Guillén-Ponce C, Martínez-Villacampa M, Pericay C.

Clin Transl Oncol. 2014 Nov;16(11):942-53. doi: 10.1007/s12094-014-1212-8. Epub 2014 Sep 16. Review.

20.

Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.

Crona DJ, Keisler MD, Walko CM.

Ann Pharmacother. 2013 Dec;47(12):1685-96. doi: 10.1177/1060028013509792. Epub 2013 Nov 1. Review.

PMID:
24259629

Supplemental Content

Support Center